Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA; University of Missouri-Kansas City, Kansas City, Missouri, USA.
Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA; University of Missouri-Kansas City, Kansas City, Missouri, USA.
JACC Cardiovasc Interv. 2023 Feb 13;16(3):261-273. doi: 10.1016/j.jcin.2023.01.003.
Percutaneous coronary intervention (PCI) is increasingly used to revascularize patients ineligible for CABG, but few studies describe these patients and their outcomes.
This study sought to describe characteristics, utility of risk prediction, and outcomes of patients with left main or multivessel coronary artery disease ineligible for coronary bypass grafting (CABG).
Patients with complex coronary artery disease ineligible for CABG were enrolled in a prospective registry of medical therapy + PCI. Angiograms were evaluated by an independent core laboratory. Observed-to-expected 30-day mortality ratios were calculated using The Society for Thoracic Surgeons (STS) and EuroSCORE (European System for Cardiac Operative Risk Evaluation) II scores, surgeon-estimated 30-day mortality, and the National Cardiovascular Data Registry (NCDR) CathPCI model. Health status was assessed at baseline, 1 month, and 6 months.
A total of 726 patients were enrolled from 22 programs. The mean SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) score was 32.4 ± 12.2 before and 15.0 ± 11.7 after PCI. All-cause mortality was 5.6% at 30 days and 12.3% at 6 months. Observed-to-expected mortality ratios were 1.06 (95% CI: 0.71-1.36) with The Society for Thoracic Surgeons score, 0.99 (95% CI: 0.71-1.27) with the EuroSCORE II, 0.59 (95% CI: 0.42-0.77) using cardiac surgeons' estimates, and 4.46 (95% CI: 2.35-7.99) using the NCDR CathPCI score. Health status improved significantly from baseline to 6 months: SAQ summary score (65.9 ± 22.5 vs 86.5 ± 15.1; P < 0.0001), Kansas City Cardiomyopathy Questionnaire summary score (54.1 ± 27.2 vs 82.6 ± 19.7; P < 0.0001).
Patients ineligible for CABG who undergo PCI have complex clinical profiles and high disease burden. Following PCI, short-term mortality is considerably lower than surgeons' estimates, similar to surgical risk model predictions but is over 4-fold higher than estimated by the NCDR CathPCI model. Patients' health status improved significantly through 6 months.
经皮冠状动脉介入治疗(PCI)越来越多地用于血管重建不适合冠状动脉旁路移植术(CABG)的患者,但很少有研究描述这些患者及其结果。
本研究旨在描述不适合 CABG 的左主干或多支血管冠状动脉疾病患者的特征、风险预测的应用和结局。
复杂冠状动脉疾病不适合 CABG 的患者被纳入前瞻性药物治疗+PCI 注册研究。由独立的核心实验室评估血管造影。使用胸外科医师协会(STS)和欧洲心脏手术风险评估系统(EuroSCORE)II 评分、外科医师估计的 30 天死亡率以及国家心血管数据注册中心(NCDR)CathPCI 模型计算观察到的与预期的 30 天死亡率比值。在基线、1 个月和 6 个月时评估健康状况。
共从 22 个项目中招募了 726 名患者。PCI 前的平均 SYNTAX(经皮冠状动脉介入治疗与紫杉醇和心脏手术的协同作用)评分是 32.4 ± 12.2,PCI 后是 15.0 ± 11.7。30 天全因死亡率为 5.6%,6 个月时为 12.3%。使用 STS 评分时观察到的与预期的死亡率比值为 1.06(95%CI:0.71-1.36),使用 EuroSCORE II 时为 0.99(95%CI:0.71-1.27),使用心脏外科医生估计时为 0.59(95%CI:0.42-0.77),使用 NCDR CathPCI 评分时为 4.46(95%CI:2.35-7.99)。从基线到 6 个月时健康状况显著改善:SAQ 综合评分(65.9 ± 22.5 与 86.5 ± 15.1;P<0.0001),堪萨斯城心肌病问卷综合评分(54.1 ± 27.2 与 82.6 ± 19.7;P<0.0001)。
不适合 CABG 而行 PCI 的患者具有复杂的临床特征和高疾病负担。PCI 后短期死亡率明显低于外科医生的估计,与手术风险模型预测相似,但高于 NCDR CathPCI 模型估计的 4 倍以上。患者的健康状况在 6 个月内显著改善。